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Figure S1. Synthesis of PIAA, PIAA analogs, and iso-PIAA. (A) Scheme for synthesis of 
PIAA and its analogs.  Reagents & Conditions: (a) methyl acrylate, Pd(OAc)2, P(o-tolyl)3, Et3N, 
CH3CN, 90 °C, 6 h. (b) LiOH, THF-MeOH-H2O (3:1:1), room temp., 10 h. (c) acrylamide, 
Pd(OAc)2, P(o-tolyl)3, Et3N, CH3CN, 90 °C, 6 h. (B) Scheme for synthesis of iso-PIAA. 
Reagents & Conditions: (a) NaNO2, AcOH, H2O, 0 °C, 1 h, then NaN3, room temp., 2 h; (b) 
FeBr2 (5 mol%), 4Å molecular sieves (100 mol%), CH2Cl2, 40 °C, 16 h. (c) methyl acrylate, 
Pd(OAc)2, P(o-tolyl)3, Et3N, CH3CN, 90 °C, 6 h. (d) LiOH, THF-MeOH-H2O (3:1:1), room 
temp., 3 h. 
 
Figure S2. Full western blot scans for Fig. 2J. The full scans for each blot are shown right. 
 
Figure S3. TBK1/IKKε-Is augment the number of the newly formed b-cells. (A) Schematic 
diagram for assessment of ablation efficiency of b-cells. (B) Quantification of the number 
(mean±SD) of newly regenerated (Green+) b-cells at 48 hpa (4.4±1.6 b-cells were green-only-
positive in DMSO-treated larvae, while 9.3±2.2 (BX795), 11.1±4.4 (amlexanox), and 18.1±3.6 
(PIAA) b-cells expressed as green-only in TBK1/IKKε-I-treated recovering larvae). Cells in 20 
planes of confocal images from 10 individual larvae were counted per condition. ***, P < 0.001. 
 
Figure S4. TBK1/IKKε inhibitors do not increase proliferation of liver cells nor lead to an 
overshoot in b-cell number. (A-C) Confocal single-plane images of [Tg(ins:CFP-NTR)s892; 
Tg(ins:Kaede)jh6] larvae at 48 hpa, concurrently treated with EdU and DMSO (A), amlexanox 
(B), or PIAA (C), respectively, from 0-48 hpa, stained for Prox1 (blue). The number of Prox1-
positive cells in the liver that incorporated EdU did not significantly increase in TBK1/IKKε-I-
treated recovering larvae (B and C) compared to DMSO-treated larvae (A). (D) The percentage 
(mean±SD) of Prox1-positive liver cells that incorporated EdU at 48 hpa (in A-C; 31.6±5.6% 
(DMSO), 30.1±5.8% (amlexanox), and 33.5±10.5% (PIAA)). Cells in 10 planes of confocal 
images from 5 individual larvae were counted per condition. (E-G) Bright-field images 
combined with fluorescent images showing the overall morphology of embryos and 
[Tg(ins:CFP-NTR)s892; Tg(ins:Kaede)jh6] expression (green) in larvae at 96 hpa treated with 
DMSO (E), amlexanox (F), and PIAA (G), respectively. While TBK1/IKKε-Is expanded 
[Tg(ins:CFP-NTR)s892; Tg(ins:Kaede)jh6]-expressing cell population (white squares and insets) 
during regeneration (F and G) compared to DMSO (E), a longer treatment (0-96 hpa) did not 
result in overproliferation of b-cells. (H-J) Confocal single-plane images of [Tg(ins:CFP-
NTR)s892; Tg(ins:Kaede)jh6] larvae at 96 hpa (in E-G), stained with Topro (blue). White arrows 
indicate b-cells located in secondary islets.  
 
Figure S5. TBK1/IKKε suppression promotes b-cell regeneration via PKA and mTOR 
signaling axis. (A-L) Bright-field images combined with fluorescent images showing the overall 
morphology and [Tg(ins:CFP-NTR)s892; Tg(ins:Kaede)jh6] expression (green) of larvae at 48 hpa 
treated with DMSO (A), calcineurin inhibitor FK506 (B), mTOR inhibitor rapamycin (C), PKA 
inhibitor PKI-(6-22)-amide (D), PI3K inhibitor LY294002 (E), Akt inhibitor MK2206 (F), PIAA 
(G), and combinations of each inhibitor with PIAA (H-L), respectively. Treatment of rapamycin 
and PKI-(6-22)-amide suppressed PIAA-mediated b-cell regeneration (G vs. I and J). The 
individual LY294002 and MK2206 caused increase in the [Tg(ins:CFP-NTR)s892; 
Tg(ins:Kaede)jh6]-expressing cell population during regeneration (E and F). The combinations of 
LY294002 or MK2206, especially MK2206, with PIAA resulted in significant increase in b-cell 
regeneration (K and L) compared to individual treatments (E and F). The insets display 
magnified views of the pancreatic islets (outlined by the dashed squares). (M-N) Quantification 
of the number (mean±SD) of total regenerated b-cells at 48 hpa (in A-L; 4.7±1.2 (DMSO), 
5.5±1.7 (FK506), 4.2±1.3 (rapamycin), 5.4±1.7 (PKI-(6-22)-amide), 8.7±1.7 (LY294002), 
14.8±2.7 (MK2206), 17.9±2.4 (PIAA), 16.7±2.3 (PIAA with FK506), 7.0±2.1 (PIAA with 
rapamycin), 9.6±2.8 (PIAA with PKI-(6-22)-amide), 21.3±4.3 (PIAA with LY294002), 31.9±5.1 
(PIAA with MK2206)). Cells in 20 planes of confocal images from 20 individual larvae were 
counted per condition. **, P < 0.01; ***, P < 0.001. (O) A model depicting the role of PKA and 
mTOR signaling pathways in mediating the b-cell regeneration response to TBK1/IKKε 
inhibition. The site of action of PIAA is shown in red, while those of LY294002 and MK2206 in 
blue.  
 
Figure S6. Dynamics of cAMP levels correlate with expansion of b-cell mass. (A) 
Quantification of cAMP levels (mean±SD) during b-cell regeneration in DMSO- and PIAA-
treated recovering larvae. Unlike 1 and 4 days-post-ablation (dpa), cAMP levels were 
significantly higher in PIAA-treated recovering larvae than in DMSO-treated larvae at 2 dpa (1 
dpa: 0.5±0.1pmol/larva (DMSO) and 0.6±0.0 pmol/larva (PIAA); 2 dpa: 0.5±0.1pmol/larva 
(DMSO) and 0.9±0.0 pmol/larva (PIAA); 4 dpa: 0.4±0.0 pmol/larva (DMSO) and 0.4±0.2 
pmol/larva (PIAA)). (B) Quantification of cAMP levels in DMSO-, cilostamide-, PIAA-, and a 
combination of cilostamide and PIAA-treated recovering larvae at 2 dpa. A combination of 
cilostamide and PIAA augmented cAMP levels compared to individual compound-treated larvae 
(0.5±0.1 pmol/larva (DMSO), 0.8±0.1 pmol/larva (cilostamide), 0.9±0.0 pmol/larva (PIAA), and 
1.4±0.2 pmol/larva (cilostamide and PIAA)). **, P < 0.01; ***, P < 0.001. 10 larvae were 
pooled per condition and data point. 
 
Figure S7. Full western blot scans for Fig. 6C. The full scans for each blot are shown right.  
 
Figure S8. Suppression of TBK1/IKKε bestows an mTOR-mediated increase in b-cell 
number via PDE3. (A-D) Bright-field images combined with fluorescent images showing the 
overall morphology and [Tg(ins:CFP-NTR)s892; Tg(ins:Kaede)jh6] expression (green) of larvae at 
48 hpa treated with DMSO (A), cilostamide (B), PIAA (C), and PIAA with cilostamide (D), 
respectively. The combination of cilostamide with PIAA resulted in increase in the [Tg(ins:CFP-
NTR)s892; Tg(ins:Kaede)jh6]-expressing cell population during regeneration (D) compared to 
individual treatment (B and C). The insets display magnified views of the pancreatic islets 
(outlined by the dashed squares). (E) Quantification of the number (mean±SD) of total 
regenerated b-cells at 48 hpa (in A-D; 4.5±1.0 (DMSO), 11.6±2.2 (cilostamide), 18.2±2.6 
(PIAA), and 24.6±3.6 (cilostamide with PIAA). Cells in 20 planes of confocal images from 20 
individual larvae were counted per condition. ***, P < 0.001. (F-I’) Confocal images of EdU-
administered [Tg(ins:CFP-NTR)s892; Tg(ins:Kaede)jh6] larvae at 48 hpa, treated with DMSO (F 
and F’) and PIAA (H and H’), respectively, or induced pde3a expression upon b-cell ablation (G 
and G’) and pde3a expression upon b-cell ablation in the presence of PIAA (I and I’), 
respectively, from 0-48 hpa, stained for pRPS6 (blue). The number of EdU-incorporated (white 
arrows) and pRPS6-positive (white arrowheads) b-cells was increased in recovering larvae 
treated with PIAA (H and H’) compared to DMSO-treated larvae (F and F’). When pde3a 
expression was induced upon b-cell ablation, PIAA-dependent increases in the number of EdU-
incorporated and pRPS6-positive b-cells were suppressed (I and I’). (J) Quantification of the 
number (mean±SD) of total regenerated b-cells (green dots) and regenerated b-cells that 
incorporated EdU with pRPS6 immunoreactivity (white dots) at 48 hpa (in F-I’; 4.8±1.2 total 
regenerated b-cells, of which 0.5±0.5 (DMSO), 4.0±1.0, of which 0.4±0.5 (pde3a 
overexpressing), 17.8±2.8, of which 8.0±1.9 (PIAA), and 8.0±2.8, of which 1.4±1.1 (pde3a 
overexpressing in the presence of PIAA) incorporated EdU with pRPS6 immunoreactivity). (K) 
The percentage (mean±SD) of regenerated b-cells that incorporated EdU with pRPS6 
immunoreactivity at 48 hpa (in F-I’; 8.9±9.8% (DMSO), 8.0±11.0% (pde3a overexpressing), 
44.8±7.6% (PIAA), and 15.3±9.9% (pde3a overexpressing in the presence of PIAA)). Cells in 20 
planes of confocal images from 10 individual larvae were counted per condition. ***, P < 0.001. 
(L) A model depicting the cAMP-PKA-mTOR signaling cascade via PDE3 that mediates b-cell 
regeneration in response to TBK1/IKKε inhibition.  The site of action of PIAA is shown in red,  
while those of LY294002 and MK2206 in blue, and cilostamide in purple.  
 
Figure S9. PIAA increases mTOR activity. Representative Western blot showing (A) 
increased pS6K1 levels with PIAA-treatment in rat INS-1 cells. The full scans for each blot are 
shown in (B).  
 
Figure S10. Full western blot scans for Fig. 7E. The full scans for each blot are shown right.  
 
Figure S11. PIAA increases b-cell proliferation during normal development in zebrafish. 
(A-B) Confocal images of [Tg(ins:CFP-NTR)s892; Tg(ins:Kaede)jh6] larvae at 6 dpf, concurrently 
treated EdU and DMSO (A) or PIAA (B), respectively, from 4-6 dpf. A small but significant 
increase in EdU incorporation (white arrows) was observed in PIAA-treated larvae (B) compared 
to DMSO-treated larvae (A) during normal development. (C) Quantification of the number 
(mean±SD) of total b-cells (green dots) and b-cells that incorporated EdU (yellow dots) (in A-B; 
38.0±3.2 total b-cells, of which 5.8±1.0 (DMSO) and 45.3±9.3, of which 11.0±3.6 (PIAA) 
incorporated EdU). (D) The percentage (mean±SD) of b-cells that incorporated EdU (in A-B; 
15.2±2.7% (DMSO) and 23.8±3.4% (PIAA)). Cells in 20 planes of confocal images from 5 
individual larvae were counted per condition. *, P < 0.05.  
 
Supplemental Experimental Procedures 
Generation of pde3a-overexpressing zebrafish 
To generate the Tg(hsp:pde3a; hsp:GFP)gt4, pde3a coding sequence was amplified (forward: 5’- 
GACGAATTCGTGACCGATGGCACTGGAAT-3’, reverse: 5’- 
GACCTCGAGTCATTCTGGATCTTTCTGGTCTTCG-3’) and cloned into a vector containing 
a multimerized minimal heat shock promoter, which drives gfp and pde3a transcription bi-




To perform chemical screens, we first aliquoted each chemical compound into two separate wells 
of a 96-well glass bottom microwell plate (Matrical Bioscience) to a final concentration of 50 
µM. Control larvae were treated with equal concentrations of DMSO in egg water. MTZ-treated 
[Tg(ins:CFP-NTR)s892; Tg(ins:Kaede)jh6] larvae were used. Five ablated larvae were pipetted into 
each well. At 48 hpa, the number and intensity of Kaede-positive cells within each larval 
pancreas were determined using a Leica M205 FA fluorescence microscope. Five compounds 
that changed the number and/or intensity of Kaede-positive cells within the pancreas in at least 
two larvae in both wells were retested at a range of concentrations from 10-100 µM. Two of the 
compounds, LY411575, a g-secretase inhibitor, and BX795, a dual suppressor of TBK1/IKKε 
and PDPK1, showed higher efficiency in b-cell regeneration at 10 µM and 50 µM respectively, 
on retesting. BX795 was further evaluated by examining the DMSO- and compound-treated 
regenerating b-cells in [Tg(ins:CFP-NTR)s892; Tg(ins:Kaede)jh6] larvae with a Zeiss LSM 700-
405 confocal microscope.   
 
Chemical treatment 
The following compounds and the concentrations are used in zebrafish: 100 µM amlexanox, 50 
µM BX795, 20 µM (E)-3-(3-phenylbenzo[c]isoxazol-5-yl)acrylic acid (PIAA), 25 µM 
cilostamide, 1 µM rapamycin, 50 µM BX912, 12.5 µM LY294002 (except when combined with 
PIAA and cilostamide, 1.25-6.25 µM), 10 µM MK2206,  10 µM PKI-(6-22)-amide, 10 µM 
FK506, 1 µM azabenzimidazole derivative 5c and 5e (kindly provided by Dr. Albert S. Baldwin, 
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill), and 20 
µM PIAA-1, PIAA-2, PIAA-3, and PIAA-4.   
 Immunohistochemistry 
Immunohistochemistry on whole-mount zebrafish larvae was performed using the following 
antibodies: mouse anti-Glucagon (1:100; Sigma), chicken anti-GFP (1:1000; Aves Labs), rabbit 
anti-Somatostatin (1:100; MP Biomedicals), rabbit anti-Prox1 (1:100; GeneTex), rabbit anti-
phospho-S6 ribosomal protein (Ser240/244) (1:100; Cell Signaling), and fluorescently 
conjugated Alexa antibodies (1:200; Molecular Probes). Nuclei were visualized with TOPRO 
(1:10000; Molecular Probes). To assess cell proliferation, zebrafish larvae were incubated with 
7µM 5-ethynyl-2’-deoxyuridine (EdU) and DMSO at 1.7% final concentration for the indicated 
time period. EdU incorporation was revealed for 30 minutes using Click-iT EdU Imaging Kit 
(Invitrogen), prior to primary antibody staining. Larvae were mounted in Vectashield (Vector 
Laboratories) and imaged on a Zeiss LSM 700-405 confocal microscope. Rabbit anti-Ki67 
(1:100; Abcam) and guinea pig anti-Insulin (1:100; Sigma) antibodies were additionally used for 
immunohistochemistry on rat INS-1 cells, mammalian islets in culture, and mice pancreata. 
Nuclei were visualized with TOPRO (1:2000; Molecular Probes). Rat INS-1 cells and islet 
samples were directly imaged in plates on a Zeiss LSM 700-405 confocal microscope. Mice 
pancreata were dissected, fixed in 4% PFA, treated with a 30% sucrose solution, then embedded 
in Tissue-Tek OCT compound (Sakura Finetek). 8 µm-thick sections were obtained by using a 
cryostat microtome (CryoStar NX70 Cryostat), stained with antibodies, mounted in Vectashield 
(Vector Laboratories), and imaged on a Zeiss LSM 700-405 confocal microscope. Two 8 µm-
thick pancreas sections (separated by 400 µm) per mouse were used to assess b-cell area. Images 
were taken after Insulin staining using a Zeiss LSM 700-405 confocal microscope, and islet 
size/area and the total areas of the sections were determined using the ZEN software (Zeiss). The 
percentage of b-cell area in each section was calculated by dividing the area of all insulin-
positive cells in one section by the total area of this section. 
  
Western blot analysis 
Zebrafish trunks containing the digestive organs from 100 larvae (per experiment) were dissected 
and extracted in lysis buffer (50 mM Tris–HCl, pH 7.4, 150 mM NaCl, 1 mM MgCl2, 0.5% 
IGEPAL, freshly added Protease Inhibitor Cocktail and PhosSTOP tablet from Sigma). The rat 
INS-1 and its derivative INS-1 832/13 cells were cultured in RPMI 1640 (Gibco) supplemented 
with 10% FBS, 1% Penicillin/Streptomycin, 10 mM HEPES, 1 mM sodium pyruvate, and 50 µM 
β-mercaptoethanol and used for experiments between passages 6-10. Cells were seeded in 6-well 
plates at 5x105 cells per well and starved for 18 hours in serum-free or 0.1% endotoxin-free BSA  
containing RPMI (2.5 mM glucose) prior to exposure to (E)-3-(3-phenylbenzo[c]isoxazol-5-
yl)acrylic acid (PIAA) for 30 minutes to 1 hour. After treatment, cells were lysed in lysis buffer 
mentioned above. Proteins were detected with the following antibodies (Cell Signaling): rabbit 
anti-phospho-p70 S6 kinase (Thr389) (1:500; product #9205), rabbit anti-p70 S6 kinase (1:1000; 
product #2708), rabbit anti-p70 S6 kinase (1:1000; product #9202), rabbit anti-IRF-3 (1:1000; 
product #4302), rabbit anti-phospho-IRF-3 (Ser396) (1:1000; product #29047), rabbit anti-Akt 
(pan) (1:1000; product #4691), rabbit anti-phospho-Akt (Thr308) (1:1000; product #13038), 
rabbit anti-phospho-Akt (Ser473) (1:1000; product #9271), rabbit anti-p44/42 MAPK (Erk1/2) 
(1:1000; product #9102), rabbit anti-phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (1:1000; 
product #4370), rabbit anti-phospho-Grb10 (Ser476) (1:1000; product #11817), rabbit anti-
phospho-S6 ribosomal protein (Ser240/244) (1:1000; product #5364), mouse anti-S6 ribosomal 
protein (1:1000; product #2317), rabbit anti-phospho-PKA substrate (RRXS*/T*) (1:1000; 
product #9624), and HRP-conjugated secondary antibodies (1:2500). 
 
Glucose and cAMP measurements 
For free glucose measurements, the zebrafish larvae were collected in 2 mL microcentrifuge 
tubes and frozen on crushed dry ice after removal of excess egg water. Upon thawing, 200 µL of 
PBS were added and the larvae were homogenized using a hand-held mechanical homogenizer. 
To measure glucose in larval extracts, 15 µL of supernatant was used and mixed for each 
reaction, and incubated for 30 minutes at 37°C in the dark. Fluorescence (excitation, 535 nm; 
emission, 590 nm) was measured using Biotek Synergy H4 Multi-Mode Plate Reader. Each 
sample was measured in triplicate. For cAMP content measurements, treated zebrafish larvae 
were collected (10 larvae were pooled per condition), homogenized in 100 µL 0.1 M HCl, and 
centrifuged at 6,000 g for 10 min at 4°C. The rat INS-1 cells were cultured, serum-starved and 
chemical-treated as described above. After treatment, cells were lysed in 200 µL 0.1 M HCl and 
centrifuged. Supernatants from all samples were collected and stored at −80°C until cAMP 
content measurements. 
 
Mammalian ex vivo islet culture  
Male Lewis rats were housed on a 12-hour light/dark cycle in a controlled climate according to 
Georgia Institute of Technology regulations under Institutional Animal Care and Use 
Committee-approved protocols. Pancreatic islets were isolated from rats by collagenase digestion 
(Liberase TL, Roche Diagnostics) and gradient purification, and then hand-picked and pooled. 
Islets were cultured overnight in CMRL-1066 (Invitrogen) supplemented with 10% FBS, 1% 
penicillin/streptomycin, and 25 mM HEPES (Invitrogen). The next day, islets were either 
directly treated with 3-(3-phenylbenzo[c]isoxazol-5-yl)acrylic acid (PIAA) for 4 days or 
dissociated with 0.05% trypsin-EDTA (Invitrogen) for 3-5 minutes with gentle agitation to aid 
cell cluster disruption. Single cells obtained from islet dissociation were plated in 96-well plates 
and allowed 48 hours to attach prior to treatment with 3-(3-phenylbenzo[c]isoxazol-5-yl)acrylic 
acid (PIAA) for 4 days. Human islets were cultured in Human Islet Media (Prodo Labs) 
supplemented with 1% penicillin/streptomycin and 10% human serum for 24-48 hours prior to 
experimentation.  
 
Glucose-stimulated insulin secretion from ex vivo islet culture 
Human and rat islets were evaluated for glucose-stimulated insulin secretion using standard 
methods. Cultured islets with 4-5 days treatment with DMSO or 40-80 µM PIAA were 
equilibrated within a column in the center of a 1 mL sandwich of Sephadex beads using 3 mM 
glucose in Krebs buffer for one hour. After equilibration, 3 replicates per group were subjected 
to 1 hour sequential incubations with Krebs low (3 mM glucose), high (16 mM glucose), and low 
again. Secreted insulin was monitored using a human or rat ELISA kit (Mercodia) and 
normalized to total DNA (PicoGreen, Invitrogen).  
 
Mice experiments 
Only mice that had fed blood glucose values of >300 mg glucose/dL were used. Mice were given 
daily intraperitoneal injections of vehicle (dimethylsulphoxide final 6.7%; formulated in 0.5% 
methylcellulose and 0.5% Tween-80) or PIAA (12.5 mg per kg body weight; formulated in 0.5% 
methylcellulose and 0.5% Tween-80). Mice were housed in pathogen-free facilities and 
maintained in the Animal Care Facilities at Mayo Clinic, Rochester, MN and Parker H. Petit 
Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA.  
 
Glucose tolerance test 
For glucose tolerance test, after a 12-hour fast, mice were given an intraperitoneal injection of 
glucose at a dose of 1-2 g per kg body weight. For insulin tolerance test, after a 6-hour fast, 0.75 
mU/g body weight of insulin was given. We measured blood glucose at basal, 30, 60, 90, and 
120 minutes from tail blood using the OneTouch Ultra glucometer (Lifescan). 
 
Assessment of insulin content 
Isolated mice pancreata were placed in acid-ethanol mixture (0.18 M HCl, 75% EtOH), 
incubated overnight (−80°C), and then homogenized; the tissue levels of insulin extracted by 
centrifugation (2,000 rpm, 15 min, 4 °C) were then determined by mouse insulin ELISA kit 
(Mercodia) and normalized to total pancreatic protein content determined by Pierce BCA protein 
assay kit (Thermo Fisher). 
 
Ki67-postive cell counting 
INS-1 cells 
To calculate the number of proliferating β-cells, an image of an area (near the center of each 
well) was taken using a Zeiss LSM 700-405 confocal microscope (10X, zoom 0.5; Image size 
1280 µM*1280 µM). The number of Ki67+ and Insulin+ double positive cells, and the total 
number of Insulin+ cells in the area were assessed with ImageJ.  
Rat islets  
To calculate the number of proliferating β-cells in cultured whole rat islets, an image of an area 
(near the edge of each islet) with Insulin+ cells was taken using a Zeiss LSM 700-405 confocal 
microscope (20X, zoom 0.5; Image size 640 µM*640 µM) The number of Ki67+ and Insulin+ 
double positive cells, and the total number of Insulin+ cells were counted with ImageJ (20 planes 
of confocal images). 5 islets per treatment were counted.  
Human islets  
To calculate the number of proliferating β-cells in dissociated cultured human islets, the total 
number of Ki67+ and INSULIN+ double positive cells in each well was manually counted using 
a Zeiss LSM 700-405 confocal microscope. The total number of INSULIN+ cells in each well 
was estimated approximately by multiplying the number of INSULIN+ cells in a single cluster of 
islet and the total number of clusters with INSULIN+ cells. 
STZ-induced diabetic mice  
To calculate the number of proliferating β-cells, images of >10 islets in two 8 µm-thick pancreas 
sections (separated by 400 µm) per animal were taken using a Zeiss LSM 700-405 confocal 
microscope. The number of Ki67+ and Insulin+ double positive cells, and the total number of 
Insulin+ cells in the same islet were counted with ImageJ (20 planes of confocal images; n=6 
mice per group). For the table 4, representative 12 islets were shown.  
 
Synthesis and chemical properties of PIAA 
Chemistry 
Compounds 1 (PIAA1), 2 (PIAA 2), 4 (PIAA), 5 (PIAA3) and 6 (PIAA4) were made from 
commercially available p-bromonitrobenzene (Figure S1A). Following a known literature 
procedure3, p-bromonitrobenzene was converted to 5-bromo-3-phenylbenzo[c]isoxazole 
(compound 1, PIAA1). Heck coupling reaction between compound 1 and methyl acrylate gave the 
benzoxazole derivative (compound 2, PIAA2) along with a by-product whose 1H NMR matched 
with the structure of the compound 3. Finally, these methyl ester compounds 2 and 3 were 
subjected to saponification reaction to give the target molecules compound 4 (PIAA) and 
compound 5 (PIAA3). Heck coupling reaction between compound 1 and acrylamide gave the 
target compound 6. 
 
Synthesis of compound 11 (iso-PIAA) was achieved starting from commercially available m-
bromoaniline (Figure S1B). Following a known literature procedure4, m-bromoaniline was 
converted to a substituted aminobenzophenone compound 7. Transformation of the amino group 
of compound 7 to an azido group followed by Fe(II)-catalyzed5 intramolecular N-O bond 
formation yielded the 6-bromo-3-phenylbenzo[c]isoxazole (compound 8).  Pd(II)-catalyzed Heck 
coupling6 of compound 8 with methyl acrylate gave the benzisoxazole derivative (compound 9) 
and a byproduct whose 1H NMR matched the structure of compound 10. Saponification of 
compound 9 gave the target molecule (compound 11, iso-PIAA).  
 
General experimental procedures 
All commercially available starting materials were used without further purification. Reaction 
solvents were either high performance liquid chromatography (HPLC) grade or American 
Chemical Society (ACS) grade and used without further purification. Analtech silica gel plates (60 
F254) were used for analytical TLC and Analtech preparative TLC plates (UV 254, 2000 µm) were 
used for purification. UV light, and anisaldehyde and iodine stains were used to visualize the spots. 
100-200 Mesh silica gel was used in column chromatography. Nuclear magnetic resonance (NMR) 
spectra were recorded on a Varian-Gemini 400 MHz or Bruker 500 MHz magnetic resonance 
spectrometer. 1H NMR spectra were recorded in parts per million (ppm) relative to the residual 
peaks of CHCl3 (7.24 ppm), CHD2OD (4.78 ppm) or DMSO-d5 (2.49 ppm). 13C spectra were 
recorded relative to the central peak of the CDCl3 triplet (77.0 ppm) or CD3OD septet (49.3 ppm) 
or DMSO-d6 septet (39.7 ppm) and were recorded with complete hetero-decoupling. High-
resolution mass spectra were recorded at the Georgia Institute of Technology mass spectrometry 
facility. 
 
Methyl (E)-3-(3-phenylbenzo[c]isoxazole-5yl)acrylate (compound 2, PIAA2). A solution of 5-
bromo-3-phenylbenzo[c]isoxazole (compound 1; 215 mg, 0.78 mmol), methyl acrylate (0.14 mL, 
0.57 mmol), palladium(II) acetate (26 mg, 0.12 mmol), tri-o-tolylphosphine (74 mg, 0.24 mmol), 
and trimethylamine (0.27 mL, 1.96 mmol) in degassed acetonitrile (3 mL) was heated at 90 °C in 
a sealed pressure tube for 6 h. Subsequently, the reaction mixture was cooled to room temperature, 
diluted with ethyl acetate (100 mL), and washed with 4M HCl (20 mL), water (20 mL), and brine 
(10 mL). The ethyl acetate portion was dried over anhydrous Na2SO4, filtered, and concentrated 
in vacuo. The crude product was purified by column chromatography (SiO2, 20% ethyl acetate in 
hexane) to afford the pure title compound 2 (PIAA2, 68 mg, 31%) as a yellow solid. 1H NMR (400 
MHz, DMSO-d6) δ 8.49 (s, 1H), 8.18 (d, J = 7.2 Hz, 2H), 7.84 (t, J = 13.2 Hz, 2H), 7.72 – 7.55 
(m, 4H), 6.72 (d, J = 16.1 Hz, 1H), 3.75 (s, 3H).  
 
Methyl (E)-3-(4-amino-3-benzophenyl)acrylate (compound 3). During the synthesis of the 
compound 2 (PIAA2), another by-product was detected by TLC and was isolated by column 
chromatography (SiO2, 50% ethyl acetate in hexane) and characterized as compound 3 (yellow 
solid, 142 mg, 65%). 1H NMR (400 MHz, DMSO-d6) δ 7.76 – 7.64 (m, 1H), 7.62 – 7.45 (m, 6H), 
7.39 (d, J = 15.7 Hz, 1H), 7.35 (d, J = 15.8 Hz, 1H), 7.25 (s, 1H), 6.89 (d, J = 8.8 Hz, 1H), 6.17 
(d, J = 15.9 Hz, 1H), 3.63 (s, 3H). HRMS (EI) m/z Calcd. for C17H15ON3 [M+]: 281.1052, found 
281.1040.  
 
(E)-3-(3-phenylbenzo[c]isoxazole-5yl)acrylic acid (compound 4, PIAA). Compound 2 (PIAA2, 
60 mg, 0.21 mmol) was dissolved in THF-MeOH-H2O (2 mL, 3:1:1) and LiOH×H2O (18 mg, 0.42 
mmol) was added to the solution. The resulting mixture was stirred at room temperature for 3 h. 
1M HCl was added to the reaction mixture to quench the reaction and pH of the solution was 
brought down to 2. The resulting solution was extracted with 10% MeOH in dichloromethane (50 
mL) and washed with water (10 mL) and brine (10 mL). The organic layer was dried over 
anhydrous Na2SO4, filtered, and concentrated in vacuo. The crude product was triturated with 
dichloromethane to give the title compound 4 (PIAA, 37 mg, 66%) as a yellow solid. 1H NMR 
(400 MHz, DMSO-d6) δ 12.43 (s, 1H), 8.45 (s, 1H), 8.18 (dd, J = 8.1, 1.4 Hz, 2H), 7.86 (d, J = 9.4 
Hz, 1H), 7.82 – 7.52 (m, 5H), 6.62 (d, J = 16.0 Hz, 1H). 13C NMR (101 MHz, DMSO-d6) δ 167.8, 
165.3, 157.4, 143.4, 131.8, 131.3, 129.8, 127.3, 126.9, 124.2, 119.9, 115.8, 114.2. HRMS (ESI) 
m/z Calcd. for C16H10O3N [M - H+]: 264.0666, found 264.0669. 
 
(E)-3-(4-amino-3-benzophenyl)acrylic acid (compound 5, PIAA3). Following the same procedure 
as described for the synthesis of compound 4 (PIAA), saponification of the compound 3 (130 mg, 
0.46 mmol) with LiOH×H2O (39 mg, 0.92 mmol) in THF-MeOH-H2O (2 mL, 3:1:1) gave the title 
compound 5 (PIAA3, 119 mg, 80%) as a yellow solid. 1H NMR (400 MHz, DMSO-d6) δ 12.01 (s, 
1H), 7.69 (d, J = 9.1 Hz, 1H), 7.67 – 7.41 (m, 7H), 7.33 (d, J = 15.9 Hz, 2H), 6.89 (d, J = 9.0 Hz, 
1H), 6.10 (d, J = 15.8 Hz, 1H). HRMS (ESI) m/z Calcd. for C16H12O3N [M - H+]: 266.0823, found 
266.0823. 
 
(E)-3-(3-phenylbenzo[c]isoxazole-5-yl)acrylamide (compound 6). Heck coupling reaction 
between compound 1 (75 mg, 0.27 mmol) and acrylamide (39 mg, 054 mmol) in presence of 
Pd(OAc)2 (9.1 mg, 0.04 mmol) gave the title compound 6 (4 mg, 5%) as yellow solid. 1H NMR 
(400 MHz, DMSO-d6) δ 8.35 (s, 1H), 8.18 (d, J = 6.8 Hz, 2H), 7.78 – 7.51 (m, 7H), 7.16 (s, 1H), 
6.68 (d, J = 16.0 Hz, 1H). HRMS (ESI) m/z Calcd. for C16H13O2N2 [M + H]: 265.0972, found 
265.0978. 
 
6-Bromo-3-phenylbenzo[c]isoxazole (compound 8). Sodium nitrite (103 mg, 1.49 mmol) was 
added to a solution of substituted aminobenzophenone derivative 7 (300 mg, 0.99 mmol) in 5 mL 
of AcOH and 5 mL of H2O at 0 °C. After 1 h of stirring at the same temperature, sodium azide (96 
mg, 1.49 mmol) was added and the resulting mixture was stirred at room temperature for 2 h. 
Reaction mixture was neutralized with a saturated aqueous Na2CO3 solution and was extracted 
with dichloromethane (50 mL). The organic layer was washed with water (20 mL) and brine (20 
mL), dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The crude product was 
used in the next step without further characterization. The crude aryl azide was mixed with dried 
4Å molecular sieve (300 mg, 100 mol%), FeBr2 (11mg, 0.05 mmol), and anhydrous 
dichloromethane (1 mL) in a sealed tube and the resultant mixture was heated at 40 °C for 16 h. 
Subsequently, the mixture was cooled and filtered. The filtrate was concentrated and the crude 
product was purified by column chromatography (SiO2, 20% ethyl acetate in hexane) to give the 
title compound 8 (163 mg, 60%) as a white solid. 1H NMR (400 MHz, CDCl3) δ 7.98 (d, J = 6.8 
Hz, 2H), 7.83 (s, 1H), 7.72 (d, J = 9.2 Hz, 1H), 7.59 - 7.51 (m, 4H). HRMS (EI) m/z Calcd. for 
C13H8ONBr [M+]: 272.9788, found 272.9789. 
 
Methyl (E)-3-(3-phenylbenzo[c]isoxazole-6yl)acrylate (compound 9). A solution of 6-bromo-3-
phenylbenzo[c]isoxazole (compound 8; 184 mg, 0.67 mmol), methyl acrylate (0.12 mL, 1.34 
mmol), palladium(II) acetate (23 mg, 0.10 mmol), tri-o-tolylphosphine (63 mg, 0.20 mmol), and 
triethylamine (0.23 mL, 1.68 mmol) in degassed acetonitrile (2 mL) was heated at 90 °C in a sealed 
pressure tube for 6 h. Subsequently, the reaction mixture was cooled to room temperature, diluted 
with ethyl acetate (100 mL), and washed with 4M HCl (20 mL), water (20 mL), and brine (10 mL). 
The ethyl acetate portion was dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. 
The crude was purified by column chromatography (SiO2, 20% ethyl acetate in hexane) to afford 
the pure title compound 9 (24 mg, 13%) as a yellow solid. 1H NMR (500 MHz, DMSO-d6) δ 8.12 
(dt, J = 12.9, 4.8 Hz, 3H), 8.03 (s, 1H), 7.78 (d, J = 16.1 Hz, 1H), 7.69 – 7.55 (m, 4H), 6.85 (d, J 
= 16.1 Hz, 1H), 3.76 (s, 3H). HRMS (ESI) m/z Calcd. for C17H14O3N [M + H+]: 280.0968, found 
280.0969. 
 
Methyl (E)-3-(3-amino-4-benzophenyl)acrylate (compound 10). The title compound 10 was 
obtained as a byproduct during the Heck coupling reaction between 6-bromo-3-
phenylbenzo[c]isoxazole (compound 8; 184 mg, 0.67 mmol) and methyl acrylate (0.12 mL, 1.34 
mmol). The yield was 73% (137 mg) [eluted with 30% ethyl acetate in hexane]. 1H NMR (500 
MHz, DMSO-d6) δ 7.65 – 7.45 (m, 6H), 7.26 (dd, J = 20.7, 8.0 Hz, 1H), 7.16 (s, 2H), 7.07 (d, J = 
1.3 Hz, 1H), 6.93 – 6.84 (m, 1H), 6.58 (d, J = 16.0 Hz, 1H), 3.73 (s, 3H). HRMS (EI) m/z Calcd. 
for C17H15ON3 [M+]: 281.1052, found 281.1038. 
 
(E)-3-(3-phenylbenzo[c]isoxazole-6yl)acrylic acid (compound 11, iso-PIAA). Compound 9 (20 
mg, 0.07 mmol) was dissolved in 2 mL of THF-MeOH-H2O (3:1:1) and LiOH×H2O (6.10 mg, 0.14 
mmol) was added to the solution. The resulting mixture was stirred at room temperature for 3 h. 
1M HCl was added to the reaction mixture to quench the reaction and pH of the solution was 
brought down to 2. The resulting solution was extracted with 10% MeOH in dichloromethane (50 
mL) and was washed with water (10 mL) and brine (10 mL). The organic layer was dried over 
anhydrous Na2SO4, filtered, and concentrated in vacuo. The crude product was triturated with 
dichloromethane to give the pure title compound 11 (iso-PIAA, 12 mg, 70%) was as a yellow 
solid. 1H NMR (500 MHz, DMSO-d6) δ 12.60 (s, 1H), 8.11 (dd, J = 13.3, 5.8 Hz, 3H), 7.97 (d, J 
= 24.6 Hz, 1H), 7.71 (d, J = 16.0 Hz, 1H), 7.68 – 7.61 (m, 2H), 7.62 – 7.54 (m, 2H), 6.81 – 6.66 
(m, 1H). 13C NMR (101 MHz, DMSO-d6) δ 167.2, 164.1, 157.6, 142.6, 137.2, 130.7, 129.6, 126.8, 




In silico docking was performed using Autodock Vina7 run through PyRx to manage the 
workflow and PyMol to visualize the results. Ligands were prepared by generating an energy 
minimized 3D structure in ChemBioDraw3D. Then the energy minimized ligands and 
macromolecule (TBK1 (PDB code: 4EUT)) were processed with Autodock Tools 1.5.4. Docking 
runs were performed within a 25−30 Å cubic search space surrounding the TBK1 binding pocket 
previously occupied by BX795. After the run, Autodock Vina ranked docking outputs according 
to binding affinity. Docking outputs were thereafter overlaid with BX795 in the TBK1 binding 
pocket to select the output that made the appropriate interactions with residues in the binding 
pocket. 
 
Elucidation of the Structure of PIAA 
PIAA was originally described as (E)-3-(3-phenylbenzo[c]isoxazol-6-yl)acrylic acid (iso-PIAA). 
However, a comparison of its docking pose with that of (E)-3-(3-phenylbenzo[c]isoxazol-5-
yl)acrylic acid (compound 4) showed that compound 4 is better accommodated at the active site 
of TBK1 than iso-PIAA (Figure 2C). The b-cell regeneration activity of compound 4 is 
indistinguishable from that of ChemDiv compound 7366-0123, the compound identified from 
ChemDiv screening collection as TBK1 inhibitor8, while iso-PIAA is inactive (data not shown). 
Moreover, compound 4 inhibits TBK1/IKKε kinase activity while iso-PIAA is inactive (Figures 
2A-2B). Finally, the 1H-NMR of compound 4 matched the 1H-NMR provided by ChemDiv. 
These data confirmed that the correct structure of PIAA is (E)-3-(3-phenylbenzo[c]isoxazol-5-
yl)acrylic acid (compound 4). 
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Supplementary table 1. Quantification of Insulin- and Ki67/Insulin-double positive cell 
number in INS-1 cells  
 
    Fields Ki67+/Ins+ Insulin+ % 
INS-1 
DMSO 
1 35 93 37.63 
2 73 152 48.03 
3 55 126 43.65 
          
PIAA 
1 158 162 97.53 
2 248 263 94.3 
3 173 211 81.99 

































Supplementary table 2. Quantification of Insulin- and Ki67/Insulin-double positive cell 
number in rat islets 
 
 
    Islets Ki67+/Ins+ Insulin+ % 
Rat 
DMSO 
1 2 210 0.95 
2 3 250 1.20 
3 2 240 0.83 
4 2 220 0.91 
5 4 240 1.67 
         
PIAA 20 µM 
1 8 200 4.00 
2 3 180 1.67 
3 4 220 1.82 
4 6 250 2.40 
5 7 190 3.68 
         
PIAA 40 µM 
1 10 200 5.00 
2 11 230 4.78 
3 5 270 1.85 
4 3 180 1.67 
5 9 180 5.00 
         
PIAA 80 µM 
1 10 180 5.56 
2 12 200 6.00 
3 10 160 6.25 
4 9 190 4.74 















Supplementary table 3. Quantification of Insulin- and Ki67/Insulin-double positive cell 
number in dissociated human islet culture  
 
 
    Wells Ki67+/INS+ INSULIN+ % 
Human 
DMSO 
1 2 1385 0.14 
2 2 1450 0.14 
3 3 1500 0.20 
4 1 1210 0.08 
5 1 1100 0.09 
          
PIAA 20 µM 
1 6 1510 0.40 
2 4 1350 0.30 
3 2 1410 0.14 
4 4 1400 0.29 
5 4 1460 0.27 
          
PIAA 40 µM 
1 7 1425 0.49 
2 4 1685 0.24 
3 5 1380 0.36 
4 6 1450 0.41 
5 5 1520 0.33 
          
PIAA 80 µM 
1 12 1545 0.78 
2 7 1400 0.50 
3 5 1450 0.34 
4 8 1350 0.59 
















Supplementary table 4. Quantification of Insulin- and Ki67/Insulin-double positive cell 
number in mice pancreata  
 
 
  Islets Ki67+/Ins+ Insulin+ % 
STZ mice 
DMSO 
1 0 48 0 
2 0 58 0 
3 0 79 0 
4 1 65 1.54 
5 0 55 0 
6 0 62 0 
7 1 143 0.7 
8 1 42 2.38 
9 1 102 0.98 
10 1 42 2.38 
11 0 68 0 
12 0 31 0 
          
PIAA 
1 1 62 1.61 
2 3 52 5.77 
3 2 64 3.13 
4 4 130 3.08 
5 2 87 2.3 
6 2 65 3.08 
7 2 96 2.08 
8 3 84 3.57 
9 4 108 3.7 
10 3 80 3.75 
11 2 141 1.42 
12 4 126 3.18 
 











